Agenus Inc
Agenus Inc (AGEN) Wheel Strategy
AGEN wheel strategy scan found 5 cash-secured put setups on the previous trading day. Probability of expiring worthless is above 50%. Annualized returns reach up to 51.7%.
Read more
Running a AGEN wheel strategy lets you generate consistent premium income on Agenus Inc while setting your own entry and exit prices on the underlying. Agenus Inc's wheel combines cash-secured puts and covered calls into a repeatable cycle: sell puts at strikes where you'd be happy to own AGEN, and if assigned, sell calls at strikes where you'd be happy to sell. Use our scanner to find the best AGEN wheel strategy setups in real time.
The wheel works best on liquid, high-quality names with stable fundamentals and active options markets — exactly the profile many large-cap leaders fit. The mechanics are simple: sell a cash-secured put on AGEN, collect premium, and either keep the premium if it expires worthless or take assignment at a discount to current price. Once assigned, sell covered calls against the shares to keep collecting premium until they're called away. Choosing the right strikes, expirations, and IV environment is what separates a profitable AGEN wheel from a losing one.
Agenus Inc., a clinical-stage immuno-oncology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies. It develops vaccine programs comprising Prophage vaccine candidate; and QS-21 Stimulon adjuvant, a saponin-based vaccine adjuvant. The company also develops Balstilimab, an anti-PD-1 antagonist that has completed Phase II clinical trial to treat second line cervical cancer; AGEN1181, an anti-CTLA-4 monospecific antibody that is in Phase 1/2 clinical trial; AGEN2373, an anti-CD137 monospecific antibody that is in Phase 1 clinical trial; AGEN1423, a tumor microenvironment conditioning anti-CD73/TGFß TRAP bi-functional antibody that has completed Phase 1 clinical trial; AGEN1777, an anti-TIGIT bispecific antibodies; and AGEN1327, a human monoclonal antibody.
The difference between a wheel that compounds and one that bleeds comes down to strike selection, IV timing, and discipline on assignment. Our scanner handles the heavy lifting: it ranks every leg of the AGEN wheel strategy by delta, premium yield, IV rank, and days to expiration, so you can deploy capital where the math works. Build your AGEN wheel strategy on data, not gut feel — and let the options wheel do what it does best: pay you to wait.
| Jan 21, 2028 | 4.00 | $0.05 | $2.43 | -0.10 | 428 | 2% | 52.5% | 51.7% | 59 |
| Feb 19, 2027 | 5.00 | $0.10 | $0.60 | -0.25 | 92 | 2% | 61.6% | 47.6% | 4 |
| Jan 15, 2027 | 5.00 | $0.05 | $0.33 | -0.22 | 57 | 2% | 68.0% | 41.6% | 936 |
| May 21, 2027 | 5.00 | $0.15 | $0.93 | -0.25 | 183 | 2% | 53.1% | 36.9% | 1 |
| Jan 21, 2028 | 3.00 | $0.05 | $1.03 | -0.10 | 428 | 2% | 64.6% | 29.1% | 6 |
As of Nov 20, 2026
Prices move. This one stays.Lock in 5 years at a special price and save $1,503. Ending soon.See the Black Friday deal →